Medtronic GuardWire Begins Controlled Roll-Out In U.S. Market
This article was originally published in The Gray Sheet
Executive Summary
Medtronic PercuSurge is planning to submit an IDE application in the next two months for a 500-600 patient trial evaluating its GuardWire distal protection device in patients with acute myocardial infarction.
You may also be interested in...
Boston Scientific Looking To Expand Urology/Gynecology Product Offerings
Boston Scientific remains open to the possibility of making an acquisition in the urology or gynecology area to boost the current 8-10% rate of revenue growth.
PercuSurge GuardWire Associated With Fewer Adverse Cardiac Events
A comparatively low rate of major adverse cardiac events (MACE) in patients treated with Medtronic/PercuSurge's GuardWire distal protection device during saphenous vein graft repair procedures contributed to a favorable FDA panel review, despite concerns about the device's malfunction rate.
PercuSurge Committed To Boston Scientific Carotid Stent Trial
PercuSurge will proceed with plans to conduct U.S. trials of its GuardWire distal protection device with Boston Scientific's WallStent for carotid angioplasty, in spite of rival Medtronic's proposed purchase of the company for $225 mil., announced Oct. 19.